Novel adenovirus vectors 'Capsid-Displaying' a human complement inhibitor

Journal of Innate Immunity

Volumn 2, Issue 4, 2010, Pages 353-359

  Seregin, Sergey S ^a   Hartman, Zachary C ^c   Appledorn, Daniel M ^a   Godbehere, Sarah ^a   Jiang, Haixiang ^c   Frank, Michael M ^c   Amalfitano, Andrea ^a,b,c  

^a Department of Microbiology and Molecular Genetics Michigan State University ^*  (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Adenovirus vectors; Alternative complement pathway; Complement regulation; Innate immunity; Recombinant adenovirus

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENT INHIBITOR; COMPLEMENT REGULATORY PEPTIDE; HYBRID PROTEIN; UNCLASSIFIED DRUG; CAPSID PROTEIN; COMPLEMENT; PEPTIDE;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; NONHUMAN; PRIORITY JOURNAL; VIRUS CAPSID; ANIMAL; COMPLEMENT ALTERNATIVE PATHWAY; DRUG EFFECTS; EVALUATION STUDY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; HUMAN ADENOVIRUS; INNATE IMMUNITY; METABOLISM;

ADENOVIRUSES, HUMAN; ANIMALS; CAPSID; CAPSID PROTEINS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT SYSTEM PROTEINS; GENETIC VECTORS; HUMANS; IMMUNITY, INNATE; PEPTIDES; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC;

EID: 77954042715     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000284368     Document Type: Article

References (29)

1. Makrides SC: Therapeutic inhibition of the complement system. Pharmacol Rev 1998; 50: 59-87.
2. Atkinson JP: C5a and Fcγ receptors: a mutual admiration society. J Clin Invest 2006; 116: 512-520.
3. Atkinson JP, Frank MM: Bypassing complement: evolutionary lessons and future implications. J Clin Invest 2006; 116: 1215-1218.
4. Mollnes TE, Song WC, Lambris JD: Complement in inflammatory tissue damage and disease. Trends Immunol 2002; 23: 61-64.
5. Kirschfink M: Controlling the complement system in inflammation. Immunopharmacology 1997; 38: 51-62. (Pubitemid 28049963)
6. Barrington R, Zhang M, Fischer M, Carroll MC: The role of complement in inflammation and adaptive immunity. Immunol Rev 2001; 180: 5-15. (Pubitemid 32472848)
7. Cichon G, Boeckh-Herwig S, Schmidt HH, Wehnes E, Muller T, Pring-Akerblom P, Burger R: Complement activation by recombinant adenoviruses. Gene Ther 2001; 8: 1794-1800. (Pubitemid 34100580)
8. Jiang H, Wang Z, Serra D, Frank MM, Amalfitano A: Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther 2004; 10: 1140-1142. (Pubitemid 39625257)
9. Kiang A, Hartman ZC, Everett RS, Serra D, Jiang H, Frank MM, Amalfitano A: Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol Ther 2006; 14: 588-598. (Pubitemid 44296088)
10. Appledorn DM, Kiang A, McBride A, Jiang H, Seregin S, Scott JM, Stringer R, Kousa Y, Hoban M, Frank MM, Amalfitano A: Wildtype adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Ther 2008; 15: 885-901. (Pubitemid 351791476)
11. Appledorn DM, McBride A, Seregin S, Scott JM, Schuldt N, Kiang A, Godbehere S, Amalfitano A: Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther 2008; 15: 1606-1617.
12. Seregin SS, Aldhamen YA, Appledorn DM, Schuldt NJ, McBride AJ, Bujold M, Godbehere SS, Amalfitano A: Cr1/2 is an important suppressor of adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies. Gene Ther 2009; 16: 1245-1259.
13. Tian J, Xu Z, Smith JS, Hofherr SE, Barry MA, Byrnes AP: Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. J Virol 2009; 83: 5648-5658.
14. Muruve DA: The innate immune response to adenovirus vectors. Hum Gene Ther 2004; 15: 1157-1166. (Pubitemid 40052429)
15. Gasque P: Complement: a unique innate immune sensor for danger signals. Mol Immunol 2004; 41: 1089-1098. (Pubitemid 39345390)
16. Sahu A, Kay BK, Lambris JD: Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol 1996; 157: 884-891. (Pubitemid 26231396)
17. Mallik B, Katragadda M, Spruce LA, Carafides C, Tsokos CG, Morikis D, Lambris JD: Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem 2005; 48: 274-286. (Pubitemid 40105266)
18. Sahu A, Morikis D, Lambris JD: Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component c3. Mol Immunol 2003; 39: 557-566. (Pubitemid 35335834)
19. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514. (Pubitemid 28145972)
20. Fontana L, Nuzzo M, Urbanelli L, Monaci P: General strategy for broadening adenovirus tropism. J Virol 2003; 77: 11094-11104. (Pubitemid 37204299)
21. Dmitriev IP, Kashentseva EA, Curiel DT: Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 2002; 76: 6893-6899.
22. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS: Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926-933. (Pubitemid 28116869)
23. Hodges BL, Evans HK, Everett RS, Ding EY, Serra D, Amalfitano A: Adenovirus vectors with the 100k gene deleted and their potential for multiple gene therapy applications. J Virol 2001; 75: 5913-5920. (Pubitemid 32553121)
24. Ng P, Graham FL: Construction of first-generation adenoviral vectors. Methods Mol Med 2002; 69: 389-414.
25. Hartman ZC, Kiang A, Everett RS, Serra D, Yang XY, Clay TM, Amalfitano A: Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol 2007; 81: 1796-1812. (Pubitemid 46214453)
26. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ: The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther 2002; 13: 129-141. (Pubitemid 34075177)
27. Seregin SS, Appledorn DM, McBride AJ, Schuldt NJ, Aldhamen YA, Voss T, Wei J, Bujold M, Nance W, Godbehere S, Amalfitano A: Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther 2009; 17: 685-696.
28. Yeatman M, Daggett CW, Lau CL, Byrne GW, Logan JS, Platt JL, Davis RD: Human complement regulatory proteins protect swine lungs from xenogeneic injury. Ann Thorac Surg 1999; 67: 769-775. (Pubitemid 29204743)
29. Brunetti-Pierri N, Stapleton GE, Palmer DJ, Zuo Y, Mane VP, Finegold MJ, Beaudet AL, Leland MM, Mullins CE, Ng P: Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther 2007; 15: 732-740. (Pubitemid 46431993)